HRP20221054T1 - Novi analozi glp-1 - Google Patents
Novi analozi glp-1 Download PDFInfo
- Publication number
- HRP20221054T1 HRP20221054T1 HRP20221054TT HRP20221054T HRP20221054T1 HR P20221054 T1 HRP20221054 T1 HR P20221054T1 HR P20221054T T HRP20221054T T HR P20221054TT HR P20221054 T HRP20221054 T HR P20221054T HR P20221054 T1 HRP20221054 T1 HR P20221054T1
- Authority
- HR
- Croatia
- Prior art keywords
- absent
- integer
- polypeptide according
- leo
- cooh
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 4
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transmission And Conversion Of Sensor Element Output (AREA)
Claims (10)
1. Polipeptid koji sadrži aminokiselinski slijed:
H-X2-X3-X4-G-T-F-T-S-D-V-S-S-Y-L-X16-G-Q-A-A-X21-E-F-X24-A-W-L-V-
R-G-R-G-X33-X34,
naznačen time što
X2 je Ser, Ser(OMe), D-Ser, D-Ser(OMe), Ala ili Aib;
X3 je odsutan ili Gln;
X4 je Glu;
X16 je Glu;
X24 je Ile;
X33 je Leu, -D-Leu, D-Ile ili Ile;
X34 je odsutan; i
X21 je Lys, gdje je amino skupina bočnog lanca (ε-amino) u Lys acilirana ostatkom:
{-Q-T-U-W-Y-Z,
gdje su Q i T odsutni;
U je odsutan ili -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-}, gdje je } mjesto vezanja sa skupinom W;
W je odsutan ili se bira iz skupine koju čine -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-], -C(O)-NH-(CH2)3-4-NH-], -C(O)-C(CH3)2-NH-], te
[image]
,
gdje je ] mjesto vezanja sa skupinom Y;
Y je -C(O)-(CH2)2-CH(COOH)NH--, gdje je -- mjesto vezanja sa skupinom Z;
Z je -C(O)-(CH2)n-COOH ili -C(O)-(CH2)n-CH3, gdje je n cijeli broj od 14 do 20.
2. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što
X2 je Aib;
X3 je odsutan;
X33 je Leu;
U je -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-};
W je -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-]; i
Z je -C(O)-(CH2)n-COOH, gdje je n cijeli broj 16.
3. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što
X2 je Aib;
X3 je odsutan;
X33 je Leu;
U je -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-};
W je -C(O)-C(CH3)2-NH-]; i
Z je -C(O)-(CH2)n-COOH, gdje je n cijeli broj 16.
4. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što
X2 je Aib;
X3 je odsutan;
X33 je Leu;
U je -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-};
W je -C(O)-NH-(CH2)4-NH-]; i
Z je -C(O)-(CH2)n-COOH, gdje je n cijeli broj 16.
5. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što
X2 je Aib;
X3 je odsutan;
X33 je Leu;
U je -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-};
W je
[image]
;
i
Z je -C(O)-(CH2)n-COOH, gdje je n cijeli broj 16.
6. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što
X2 je Aib;
X3 je odsutan;
X33 je Leu;
U je -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-};
W je -C(O)-NH-(CH2)3-NH-]; i
Z je -C(O)-(CH2)n-COOH, gdje je n cijeli broj 16.
7. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što
X2 je Ser, Ser(OMe), D-Ser, D-Ser(OMe);
X3 je odsutan;
X33 je Leu;
U je -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-};
W je -C(O)-CH2-O-(CH2)2-O-(CH2)2-NH-], -C(O)-NH-(CH2)3-4-NH-], -C(O)-C(CH3)2-NH-]; i
Z je -C(O)-(CH2)n-COOH ili -C(O)-(CH2)n-CH3, gdje je n cijeli broj od 14 do 20.
8. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što se W bira iz skupine koju čine -C(O)-NH-(CH2)3-4-NH-], -C(O)-C(CH3)2-NH-], te
[image]
.
9. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što
X2 je Ala;
X3 je odsutan;
X33 je Leu;
W je odsutan;
Z je -C(O)-(CH2)n-CH3, gdje je n cijeli broj 14.
10. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što
X2 je Aib;
X3 je odsutan;
X33 je Leu;
W je odsutan;
Z je -C(O)-(CH2)n-CH3, gdje je n cijeli broj 14.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821013109 | 2018-04-05 | ||
| IN201821040468 | 2018-10-26 | ||
| IN201821040474 | 2018-10-26 | ||
| EP19724915.4A EP3774862B1 (en) | 2018-04-05 | 2019-04-05 | Novel glp-1 analogues |
| PCT/IB2019/052835 WO2019193576A1 (en) | 2018-04-05 | 2019-04-05 | Novel glp-1 analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221054T1 true HRP20221054T1 (hr) | 2022-11-11 |
Family
ID=66589592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221054TT HRP20221054T1 (hr) | 2018-04-05 | 2019-04-05 | Novi analozi glp-1 |
| HRP20240749TT HRP20240749T1 (hr) | 2018-04-05 | 2019-04-05 | Novi analozi glp-1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240749TT HRP20240749T1 (hr) | 2018-04-05 | 2019-04-05 | Novi analozi glp-1 |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US11447535B2 (hr) |
| EP (3) | EP4122954B1 (hr) |
| JP (2) | JP7250814B2 (hr) |
| KR (1) | KR20200141469A (hr) |
| CN (2) | CN112236444A (hr) |
| AU (2) | AU2019247936C1 (hr) |
| BR (1) | BR112020020419A2 (hr) |
| CA (1) | CA3095988A1 (hr) |
| CL (1) | CL2020002574A1 (hr) |
| CO (1) | CO2020012425A2 (hr) |
| DK (2) | DK3774862T3 (hr) |
| EC (1) | ECSP20070185A (hr) |
| ES (2) | ES2925678T3 (hr) |
| FI (1) | FI4122954T3 (hr) |
| HR (2) | HRP20221054T1 (hr) |
| HU (1) | HUE060135T2 (hr) |
| IL (1) | IL277483A (hr) |
| JO (1) | JOP20200251A1 (hr) |
| LT (2) | LT3774862T (hr) |
| MX (2) | MX2020010505A (hr) |
| PE (1) | PE20211417A1 (hr) |
| PH (1) | PH12020551591A1 (hr) |
| PL (2) | PL4122954T3 (hr) |
| PT (2) | PT3774862T (hr) |
| RS (2) | RS65639B1 (hr) |
| SG (1) | SG11202009467YA (hr) |
| SI (2) | SI4122954T1 (hr) |
| UA (1) | UA128210C2 (hr) |
| WO (1) | WO2019193576A1 (hr) |
| ZA (1) | ZA202306729B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4122954T3 (pl) * | 2018-04-05 | 2024-08-12 | Sun Pharmaceutical Industries Limited | Nowe analogi GLP-1 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| TW202216746A (zh) * | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| PE20231309A1 (es) * | 2020-10-17 | 2023-08-24 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip |
| CN114685646B (zh) * | 2020-12-31 | 2023-04-07 | 厦门赛诺邦格生物科技股份有限公司 | 一种多肽侧链类似物的制备方法及其应用 |
| JP2023554693A (ja) | 2021-01-20 | 2023-12-28 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| CN116514952B (zh) * | 2022-10-13 | 2024-02-02 | 江苏师范大学 | 一类glp-1类似物及其应用 |
| CN117756914B (zh) * | 2023-12-15 | 2024-09-03 | 瀚晖制药有限公司 | 依柯胰岛素的制备方法 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
| PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| JP2002508162A (ja) | 1998-02-27 | 2002-03-19 | ノボ ノルディスク アクティーゼルスカブ | Ｎ末端を短縮したｇｌｐ−１誘導体 |
| JP2003522099A (ja) | 1998-02-27 | 2003-07-22 | ノボ ノルディスク アクティーゼルスカブ | 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン |
| DE69942306D1 (de) | 1998-02-27 | 2010-06-10 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
| FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2322545A1 (en) | 1998-12-07 | 2011-05-18 | Ipsen Pharma | Analogues of GLP-1 |
| PL206302B1 (pl) | 2000-06-16 | 2010-07-30 | Elli Lilly And Companyelli Lilly And Company | Związek GLP-1 |
| US7271149B2 (en) | 2000-12-07 | 2007-09-18 | Eli Lilly And Company | GLP-1 fusion proteins |
| BR0306706A (pt) | 2002-01-08 | 2007-03-27 | Lilly Co Eli | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
| KR20050049525A (ko) | 2002-10-11 | 2005-05-25 | 가부시키가이샤산와카가쿠켄큐쇼 | Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제 |
| WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
| ES2383752T3 (es) | 2003-05-15 | 2012-06-26 | Trustees Of Tufts College | Analogos estables de GLP-1 |
| BRPI0414539B8 (pt) | 2003-09-19 | 2021-05-25 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
| JP2007536214A (ja) | 2003-12-16 | 2007-12-13 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｇｌｐ−１類似体 |
| EP1799710A2 (en) | 2004-10-07 | 2007-06-27 | Novo Nordisk A/S | Protracted glp-1 compounds |
| MX2007011307A (es) | 2005-03-18 | 2007-10-08 | Novo Nordisk As | Compuestos de glp-1 extendidos. |
| TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2006121860A2 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| JP2009507844A (ja) | 2005-09-08 | 2009-02-26 | トラスティーズ オブ タフツ カレッジ | 安定化ｇｌｐ−１類似体 |
| ES2336575T3 (es) | 2005-09-22 | 2010-04-14 | Biocompatibles Uk Limited | Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa. |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| CA2702289A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| CN102791731B (zh) | 2009-12-16 | 2016-04-20 | 诺沃—诺迪斯克有限公司 | Glp-1类似物和衍生物 |
| US8951959B2 (en) | 2010-04-27 | 2015-02-10 | Betta Pharmaceuticals Co., Ltd. | Glucagon-like peptide-1 analogues and uses thereof |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| ES2913803T3 (es) | 2010-11-09 | 2022-06-06 | Novo Nordisk As | Derivados de GLP-1 diacilados |
| EP3225631B1 (en) | 2011-04-12 | 2019-01-09 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| ES2626013T3 (es) | 2011-09-06 | 2017-07-21 | Novo Nordisk A/S | Derivados de GLP-1 |
| EP2578599A1 (en) | 2011-10-07 | 2013-04-10 | LanthioPep B.V. | Cyclic analogs of GLP-1 and GLP-1 related peptides |
| EP2846823B1 (en) | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US11274135B2 (en) | 2012-05-08 | 2022-03-15 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| MX2014015423A (es) | 2012-06-14 | 2015-04-09 | Sanofi Sa | Analogos de peptido de exedina-4. |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| TWI617574B (zh) | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| PE20151239A1 (es) | 2012-12-21 | 2015-09-08 | Sanofi Sa | Derivados de exendina-4 funcionalizada |
| EP3010546B1 (en) | 2013-06-20 | 2017-08-09 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2014209886A1 (en) | 2013-06-23 | 2014-12-31 | Wisconsin Alumni Research Foundation | Alpha/beta-polypeptide analogs of glucagon-like peptid-1 |
| JP6139712B2 (ja) | 2013-07-04 | 2017-05-31 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１様ペプチドの誘導体及びその使用 |
| EP3033112B1 (en) | 2013-08-15 | 2020-10-07 | Novo Nordisk A/S | Glp-1 derivatives, and uses thereof |
| DK3057984T3 (en) * | 2013-10-17 | 2018-10-08 | Zealand Pharma As | ACYLED GLUCAGON ANALOGS |
| WO2015086686A2 (en) | 2013-12-13 | 2015-06-18 | Medimmune Limited | Protease resistant peptides |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| ES2739289T3 (es) | 2014-11-27 | 2020-01-30 | Novo Nordisk As | Derivados de GLP-1 y sus usos |
| CN107108714B (zh) | 2014-12-17 | 2022-02-08 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| TWI726889B (zh) | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
| WO2017035432A1 (en) | 2015-08-26 | 2017-03-02 | Robert Doyle | Coagonists of glucagon-like peptide 1 receptor and neuropeptide y2 receptor |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| CA3025592A1 (en) | 2016-06-09 | 2017-12-14 | Medimmune Limited | Protease-resistant mono-lipidated peptides |
| WO2018083335A1 (en) | 2016-11-07 | 2018-05-11 | Novo Nordisk A/S | Dchbs-active esters of peg compounds and their use |
| TW201833131A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物 |
| WO2018178796A1 (en) * | 2017-03-27 | 2018-10-04 | Sun Pharmaceutical Industries Limited | Method for making kex1 protease sensitive polypeptides using yeast strain |
| CA3093221A1 (en) | 2018-03-09 | 2019-09-12 | Enzypep B.V. | Chemo-enzymatic synthesis of liraglutide, semaglutide and glp-1 |
| PL4122954T3 (pl) * | 2018-04-05 | 2024-08-12 | Sun Pharmaceutical Industries Limited | Nowe analogi GLP-1 |
-
2019
- 2019-04-05 PL PL22177403.7T patent/PL4122954T3/pl unknown
- 2019-04-05 SG SG11202009467YA patent/SG11202009467YA/en unknown
- 2019-04-05 RS RS20240706A patent/RS65639B1/sr unknown
- 2019-04-05 US US16/376,190 patent/US11447535B2/en active Active
- 2019-04-05 CA CA3095988A patent/CA3095988A1/en active Pending
- 2019-04-05 PT PT197249154T patent/PT3774862T/pt unknown
- 2019-04-05 HR HRP20221054TT patent/HRP20221054T1/hr unknown
- 2019-04-05 HU HUE19724915A patent/HUE060135T2/hu unknown
- 2019-04-05 MX MX2020010505A patent/MX2020010505A/es unknown
- 2019-04-05 BR BR112020020419-6A patent/BR112020020419A2/pt unknown
- 2019-04-05 PT PT221774037T patent/PT4122954T/pt unknown
- 2019-04-05 PL PL19724915.4T patent/PL3774862T3/pl unknown
- 2019-04-05 SI SI201930764T patent/SI4122954T1/sl unknown
- 2019-04-05 DK DK19724915.4T patent/DK3774862T3/da active
- 2019-04-05 LT LTEPPCT/IB2019/052835T patent/LT3774862T/lt unknown
- 2019-04-05 LT LTEP22177403.7T patent/LT4122954T/lt unknown
- 2019-04-05 RS RS20220814A patent/RS63523B1/sr unknown
- 2019-04-05 JO JOP/2020/0251A patent/JOP20200251A1/ar unknown
- 2019-04-05 EP EP22177403.7A patent/EP4122954B1/en active Active
- 2019-04-05 CN CN201980037166.1A patent/CN112236444A/zh active Pending
- 2019-04-05 ES ES19724915T patent/ES2925678T3/es active Active
- 2019-04-05 EP EP24161843.8A patent/EP4364751A3/en active Pending
- 2019-04-05 DK DK22177403.7T patent/DK4122954T3/da active
- 2019-04-05 CN CN202311777728.0A patent/CN117964735A/zh active Pending
- 2019-04-05 EP EP19724915.4A patent/EP3774862B1/en active Active
- 2019-04-05 JP JP2020553627A patent/JP7250814B2/ja active Active
- 2019-04-05 WO PCT/IB2019/052835 patent/WO2019193576A1/en active Application Filing
- 2019-04-05 UA UAA202006178A patent/UA128210C2/uk unknown
- 2019-04-05 PE PE2020001535A patent/PE20211417A1/es unknown
- 2019-04-05 FI FIEP22177403.7T patent/FI4122954T3/fi active
- 2019-04-05 KR KR1020207031696A patent/KR20200141469A/ko active Search and Examination
- 2019-04-05 SI SI201930322T patent/SI3774862T1/sl unknown
- 2019-04-05 AU AU2019247936A patent/AU2019247936C1/en active Active
- 2019-04-05 HR HRP20240749TT patent/HRP20240749T1/hr unknown
- 2019-04-05 ES ES22177403T patent/ES2980707T3/es active Active
-
2020
- 2020-08-04 US US16/985,207 patent/US11242373B2/en active Active
- 2020-09-21 IL IL277483A patent/IL277483A/en unknown
- 2020-09-29 PH PH12020551591A patent/PH12020551591A1/en unknown
- 2020-10-02 CO CONC2020/0012425A patent/CO2020012425A2/es unknown
- 2020-10-05 MX MX2024007688A patent/MX2024007688A/es unknown
- 2020-10-05 CL CL2020002574A patent/CL2020002574A1/es unknown
- 2020-11-05 EC ECSENADI202070185A patent/ECSP20070185A/es unknown
- 2020-12-28 US US17/134,982 patent/US11485766B2/en active Active
-
2022
- 2022-08-01 US US17/816,577 patent/US11873328B2/en active Active
- 2022-08-12 US US17/819,466 patent/US11866477B2/en active Active
-
2023
- 2023-03-22 JP JP2023045498A patent/JP2023078367A/ja active Pending
- 2023-06-01 AU AU2023203430A patent/AU2023203430A1/en active Pending
- 2023-06-30 ZA ZA2023/06729A patent/ZA202306729B/en unknown
- 2023-11-21 US US18/515,712 patent/US20240199718A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221054T1 (hr) | Novi analozi glp-1 | |
| RU99106518A (ru) | Glp-1 производные | |
| HRP20210394T1 (hr) | Moduliranje specifičnosti strukturiranog polipeptida | |
| ES2558842T3 (es) | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad | |
| JP2023078367A5 (hr) | ||
| ES2558330T3 (es) | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo | |
| RU2012101274A (ru) | Соединения глюкагона, активные в отношении рецептора gip | |
| RU2018131246A (ru) | Стабилизированные жидкие ферментные композиции | |
| ES2572260T3 (es) | Péptidos útiles en el tratamiento y/o cuidado de la piel y/o membranas mucosas y su uso en composiciones cosméticas o farmacéuticas | |
| JP2006502741A5 (hr) | ||
| PE20142113A1 (es) | Analogos de glucagon | |
| AR081339A1 (es) | Conjugados peptidicos | |
| JP2013518115A5 (hr) | ||
| HRP20191292T1 (hr) | Derivati fgf21 i njihova upotreba | |
| EP2676673A3 (en) | Glucagon/glp-1 receptor co-agonists | |
| KR900006363A (ko) | 신규한 펩티다제 억제제 | |
| RU2009128979A (ru) | Hla*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция | |
| MX2009008241A (es) | Co-agonistas de receptor de glucagon/glp-1. | |
| NO20084002L (no) | Peptider og peptid derivater savel som farmasoytiske sammensetninger inneholdende det samme | |
| RU2013147468A (ru) | Сайт-специфически монопегилированные аналоги эксендина и способ их получения | |
| RU2020120797A (ru) | Пептидные композиции | |
| DE3875538D1 (de) | Aminoluciferine, verfahren zu deren herstellung und ihre verwendung. | |
| JP2008520658A5 (hr) | ||
| WO2005115174A3 (fr) | Conjugues dipeptidiques antagonistes de l’alpha-msh | |
| ATE489462T1 (de) | Antimikrobielles polypeptid und nutzung davon |